Major surgical procedures can alter intestinal microbiota and disrupt the intestinal barrier function, leaving the patient at risk for infection. Probiotics are defined as live microorganisms that confer a health benefit on the host when administered in adequate amounts. Although the efficacy of administering probiotics perioperatively to adults has been reported, the clinical significance of probiotics in children undergoing surgery is still unclear. This study provides a brief overview of our randomized controlled trial of preoperative probiotic administration to children, and discusses the relationship between probiotics and their effects in the perioperative period, particularly focusing on bacteremia.

Journal Section:
Review Article
Keywords:
Probiotics, Intestinal microbiota, Bacteremia, Surgery, Children
1.
Deitch EA, Bridges RM: Effect of stress and trauma on bacterial translocation from the gut. J Surg Res 1987;42:536-542.
2.
Mizuno T, Yokoyama Y, Nishio H, et al: Intraoperative bacterial translocation detected by bacterium-specific ribosomal RNA-targeted reverse-transcriptase polymerase chain reaction for the mesenteric lymph node strongly predicts postoperative infectious complications after major hepatectomy for biliary malignancies. Ann Surg 2010;252:1013-1019.
3.
Baker GM, O'Brien SM, Welke KF, et al: Major infection after pediatric cardiac surgery: a risk estimation model. Ann Thorac Surg 2010;89:843-850.
4.
Reid G: Food and Agricultural Organization of the United Nation and the WHO: The importance of guidelines in the development and application of probiotics. Curr Pharm Des 2005;11:11-16.
5.
Asahara T, Nomoto K, Shimizu K, et al: Increased resistance of mice to Salmonella enterica serovar Typhimurium infection by synbiotic administration of Bifidobacteria and transgalactosylated oligosaccharides. J Appl Microbiol 2001;91:985-996.
6.
Yasui H, Ohwaki M: Enhancement of immune response in Peyer's patch cells cultured with Bifidobacterium breve. J Dairy Sci 1991,74:1187-1195.
7.
Barraud D, Blard C, Hein F, et al: Probiotics in the critically ill patient: a double blind, randomized, placebo-controlled trial. Intensive Care Med 2010;36:1540-1547.
8.
Shimizu K, Ogura H, Goto M, et al: Synbiotics decrease the incidence of septic complications in patients with severe SIRS: a preliminary report. Dig Dis Sci 2009;54:1071-1078.
9.
Sugawara G, Nagino M, Nishio H, et al: Perioperative synbiotic treatment to prevent postoperative infectious complications in biliary cancer surgery: a randomized controlled trial. Ann Surg 2006;244:706-714.
10.
Usami M, Miyoshi M, Kanbara Y, et al: Effects of perioperative synbiotic treatment on infectious complications, intestinal integrity, and fecal flora and organic acids in hepatic surgery with or without cirrhosis. J Parenter Enteral Nutr 2011;35:317-328.
11.
Tanaka K, Yano M, Motoori M, et al: Impact of perioperative administration of synbiotics in patients with esophageal cancer undergoing esophagectomy: a prospective randomized controlled trial. Surgery 2012;152:832-842.
12.
Yokoyama Y, Nishigaki E, Abe T, et al: Randomized clinical trial of the effect of perioperative synbiotics versus no synbiotics on bacterial translocation after oesophagectomy. Br J Surg 2014;101:189-199.
13.
Murakami H, Shimomura Y, Matsumoto M, et al: Intestinal microbiota in neonates requiring urgent surgery: assessing the role of probiotics using fecal DNA sequencing. Pediatr Surg Int 2016;32:37-43.
14.
Powell WT, Borghese RA, Kalanetra KM, et al: Probiotic administration in infants with gastroschisis: a pilot randomized placebo-controlled trial. J Pediatr Gastroenterol Nutr 2016;62:852-857.
15.
Wang X, Li Z, Xu Z, et al: Probiotics prevent Hirschsprung's disease-associated enterocolitis: a prospective multicenter randomized controlled trial. Int J Colorectal Dis 2015;30:105-110.
16.
El-Sawaf, Siddiqui S, Mahmoud M, et al: Probiotic prophylaxis after pullthrough for Hirschsprung disease to reduce incidence of enterocolitis: a prospective, randomized, double-blind, placebo-controlled, multicenter trial. J Pediatr Surg 2013;48:111-117.
17.
Okazaki T, Asahara T, Yamataka A, et al: Intestinal microbiota in pediatric surgical cases administered Bifidobacterium breve: a randomized controlled trial. J Pediatr Gastroenterol Nutr 2016;63:46-50.
18.
Tojo M, Oikawa T, Morikawa Y, et al: The effects of Bifidobacterium breve administration on Campylobacter enteritis. Acta Paediatr Jpn 1987;29:160-167.
19.
Umenai T, Shime N, Asahara T, et al: A pilot study of Bifidobacterium breve in neonates undergoing surgery for congenital heart disease. J Intensive Care 2014;2:36.
20.
Kanamori Y, Iwanaka T, Sugiyama M, et al: Early use of probiotics is important therapy in infants with severe congenital anomaly. Pediatr Int 2010;52:362-367.
21.
Bartosch S, Woodmansey EJ, Paterson JC, et al: Microbiological effects of consuming a synbiotic containing Bifidobacterium bifidum, Bifidobacterium lactis, and oligofructose in elderly persons, determined by real-time polymerase chain reaction and counting of viable bacteria. Clin Infect Dis 2005;40:28-37.
22.
Mitsuoka T: Significance of dietary modulation of intestinal flora and intestinal environment. Biosci Microflora 2000;19:15-25.
23.
Takagi A, Matsuzaki T, Sato M, et al: Inhibitory effect of oral administration of Lactobacillus casei on 3-methylcholanthrene-induced carcinogenesis in mice. Med Microbiol Immnol 1999;188:111-116.
24.
Yasui H, Nagaoka N, Hayakawa K: Augmentation of anti-influenza virus hemagglutinin antibody production by Peyer's patch cells with Bifidobacterium breve YIT4064. Clin Diagn Lab Immunol 1994;1:244-246.
25.
Kato I, Tanaka K, Yokokura T: Lactic acid bacterium potently induces the production of interleukin-12 and interferon-gamma by mouse splenocytes. Int J Immunopharmacol 1999;21:121-131.
26.
Takagi A, Matsuzaki T, Sato M, et al: Enhancement of natural killer cytotoxicity delayed murine carcinogenesis by a probiotic microorganism. Carcinogenesis 2001;22:599-605.
© 2017 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2017
You do not currently have access to this content.